

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20959> holds various files of this Leiden University dissertation.

Author: Diepstraten, Jeroen

Title: The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

Issue Date: 2013-06-13

The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults

Focus on propofol and nadroparin

Jeroen Diepstraten

The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults

Focus on propofol and nadroparin

The research presented in this thesis was performed at the Department of Clinical Pharmacy of the St. Antonius Hospital Nieuwegein, The Netherlands and the Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA and the Department of Anaesthesiology, St Lucas Andreas Hospital, Amsterdam, the Netherlands.

Financial Support for the publication of the thesis was provided by the St. Antonius Hospital, the Department of Clinical Pharmacy of the St. Antonius Hospital, the Department of Anesthesiology, Intensive Care and Pain Management of the St. Antonius Hospital and the Dutch Society of Metabolic and Bariatric Surgery.

ISBN: 9789491356018
Cover Design & Layout: MARLY VAN LIPZIG - (www.marlyvanlipzig.com)
Printed by: Jubels bv – Amsterdam (www.jubels.nl)
Copyright: The copyright of the articles that have been published are transferred to the respective journals

© 2013 by J. Diepstraten
No part of this thesis may be reproduced or transmitted, in any form or by any means without written permission from the author.

Proefschrift

ter verkrijging van de graad van
Doctor aan de Universiteit
Leiden, op gezag van Rector
Magnificus prof. mr. C.J.J.M.
Stolker, volgens besluit van
het College voor Promoties te
verdedigen op donderdag 13 juni
2013 klokke 11.15 uur

door Jeroen Diepstraten,
geboren te Eindhoven in 1979

Promotoren: Prof. dr. C.A.J. Knibbe
Prof. dr. A.A. Vinks
University of Cincinnati, Cincinnati, OH, USA

Co-promotoren: Dr. H.P.A. van Dongen
Dr. B. van Ramshorst

Overige leden: Prof. dr. L.P.H.J. Aarts
Prof. dr. M. Danhof
Prof. dr. H.J. Guchelaar
Prof. dr. T. Hankemeier
Prof. dr. M.M.R.F. Struys
Rijksuniversiteit Groningen

Wer schaffen will, muß fröhlich sein.
Theodor Fontane

Table of contents

Section 01 Introduction and background

01	Introduction and outline	12
-----------	--------------------------	----

02	Impact of obesity on drug metabolism and elimination in adults and children	22
-----------	---	----

The influence of morbidly obesity on the pharmacokinetics and pharmacodynamics of propofol in adults and adolescents

Section 02

03	Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients	78
-----------	---	----

04	Population pharmacokinetics and pharmacodynamics of propofol in morbidly receiving propofol-remifentanyl or propofol-epidural anaesthesia	102
-----------	---	-----

05	Prospective clinical evaluation of a model-based dosing regimen for propofol anaesthesia in morbidly obese patients	112
-----------	---	-----

06	Propofol clearance in morbidly obese children and adolescents. Influence of age and body size	128
-----------	---	-----

07	An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and non-obese adults, adolescents and children	146
-----------	---	-----

Section 03 The influence of morbidly obesity on the pharmacodynamics of nadroparin in adults

08	Treatment of pulmonary embolism in an extremely obese patient	168
-----------	---	-----

09	Thromboprophylaxis in obese surgical patients in the Netherlands, current practice and a review of the available guidelines	178
-----------	---	-----

10	Anti-Xa levels 4 h after subcutaneous administration of 5,700 IU nadroparin strongly correlate with lean body weight in morbidly obese patients	190
-----------	---	-----

11	Population pharmacodynamic model for low-molecular-weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint	202
-----------	--	-----

Section 04 Summary and perspectives

12	The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults	224
-----------	---	-----

	<i>Dutch summary</i>	236
--	----------------------	-----

	<i>List of co-authors</i>	248
--	---------------------------	-----

	<i>List of publications</i>	252
--	-----------------------------	-----

	<i>Acknowledgements</i>	256
--	-------------------------	-----

	<i>Curriculum Vitae</i>	260
--	-------------------------	-----